Abbott Laboratories ROE 2006-2018 | ABT
Current and historical return on equity (ROE) values for Abbott Laboratories (ABT) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Abbott Laboratories ROE for the three months ending September 30, 2018 was 16.05%.
| Abbott Laboratories ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2018-09-30 | $0.89B | $30.90B | 2.85% |
| 2018-06-30 | $0.93B | $30.77B | 2.95% |
| 2018-03-31 | $0.48B | $31.60B | 1.50% |
| 2017-12-31 | $0.48B | $31.10B | 1.51% |
| 2017-09-30 | $2.10B | $32.22B | 7.23% |
| 2017-06-30 | $1.17B | $31.79B | 4.46% |
| 2017-03-31 | $1.50B | $31.55B | 6.40% |
| 2016-12-31 | $1.40B | $20.72B | 6.73% |
| 2016-09-30 | $1.37B | $20.90B | 6.53% |
| 2016-06-30 | $2.28B | $20.80B | 10.82% |
| 2016-03-31 | $2.45B | $20.84B | 11.31% |
| 2015-12-31 | $4.42B | $21.33B | 20.18% |
| 2015-09-30 | $4.56B | $21.22B | 20.74% |
| 2015-06-30 | $4.52B | $23.13B | 20.14% |
| 2015-03-31 | $4.20B | $21.99B | 18.60% |
| 2014-12-31 | $2.28B | $21.64B | 9.95% |
| 2014-09-30 | $1.97B | $22.99B | 8.25% |
| 2014-06-30 | $2.40B | $23.70B | 9.96% |
| 2014-03-31 | $2.41B | $23.49B | 10.14% |
| 2013-12-31 | $2.58B | $25.27B | 10.94% |
| 2013-09-30 | $3.04B | $23.79B | 12.70% |
| 2013-06-30 | $4.02B | $22.43B | 16.22% |
| 2013-03-31 | $5.27B | $22.68B | 20.82% |
| 2012-12-31 | $5.96B | $26.81B | 22.93% |
| 2012-09-30 | $6.53B | $27.10B | 25.67% |
| 2012-06-30 | $4.89B | $24.57B | 19.69% |
| 2012-03-31 | $5.11B | $25.54B | 20.18% |
| 2011-12-31 | $4.73B | $24.53B | 18.84% |
| 2011-09-30 | $4.55B | $24.69B | 18.45% |
| 2011-06-30 | $5.14B | $26.47B | 21.54% |
| 2011-03-31 | $4.49B | $24.72B | 20.18% |
| 2010-12-31 | $4.63B | $22.77B | 21.71% |
| 2010-09-30 | $4.73B | $21.48B | 22.06% |
| 2010-06-30 | $5.31B | $20.00B | 24.84% |
| 2010-03-31 | $5.31B | $21.01B | 24.84% |
| 2009-12-31 | $5.75B | $23.19B | 27.87% |
| 2009-09-30 | $5.74B | $21.38B | 29.91% |
| 2009-06-30 | $5.35B | $19.92B | 28.61% |
| 2009-03-31 | $5.38B | $17.98B | 29.17% |
| 2008-12-31 | $4.88B | $17.52B | 26.45% |
| 2008-09-30 | $4.55B | $19.35B | 24.55% |
| 2008-06-30 | $4.18B | $18.96B | 23.76% |
| 2008-03-31 | $3.85B | $17.98B | 23.05% |
| 2007-12-31 | $3.61B | $17.82B | 22.87% |
| 2007-09-30 | $1.93B | $15.61B | 13.00% |
| 2007-06-30 | $1.93B | $15.33B | 12.99% |
| 2007-03-31 | $1.55B | $14.32B | 10.47% |
| 2006-12-31 | $1.72B | $14.05B | 11.58% |
| 2006-09-30 | $3.17B | $15.63B | 21.24% |
| 2006-06-30 | $3.13B | $15.19B | 21.50% |
| 2006-03-31 | $3.40B | $14.44B | 23.64% |
| 2005-12-31 | $3.37B | $14.42B | 23.56% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $126.526B | $27.390B |
| Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. They have a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $126.543B | 19.40 |
| Stryker (SYK) | United States | $64.420B | 24.28 |
| Boston Scientific (BSX) | United States | $51.491B | 26.02 |
| Baxter (BAX) | United States | $35.393B | 22.86 |
| Zimmer Biomet Holdings (ZBH) | United States | $23.875B | 15.48 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.038B | 0.00 |
| ResMed (RMD) | United States | $14.846B | 28.31 |
| Perrigo (PRGO) | Ireland | $8.596B | 13.05 |
| Bio-Rad Laboratories (BIO) | United States | $8.274B | 52.91 |
| Canopy Growth (CGC) | Canada | $8.174B | 0.00 |
| Hill-Rom Holdings (HRC) | United States | $6.270B | 19.88 |
| Aurora Cannabis (ACB) | Canada | $6.172B | 33.68 |
| Haemonetics (HAE) | United States | $5.727B | 50.36 |
| ICU Medical (ICUI) | United States | $4.968B | 27.68 |
| Insulet (PODD) | United States | $4.838B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $4.052B | 0.00 |
| Hutchison China MediTech (HCM) | China | $4.010B | 0.00 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $3.990B | 0.00 |
| Neogen (NEOG) | United States | $3.294B | 49.88 |
| NuVasive (NUVA) | United States | $3.166B | 29.46 |
| National Vision Holdings (EYE) | United States | $3.024B | 58.49 |
| Quidel (QDEL) | United States | $2.507B | 32.68 |
| Aphria (APHA) | $2.433B | 0.00 | |
| NxStage Medical (NXTM) | United States | $1.933B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.409B | 19.95 |
| AtriCure (ATRC) | United States | $1.241B | 0.00 |
| Cardiovascular Systems (CSII) | United States | $1.058B | 1524.50 |
| VAREX IMAGING (VREX) | United States | $0.999B | 20.07 |
| Meridian Bioscience (VIVO) | United States | $0.823B | 26.23 |
| Surmodics (SRDX) | United States | $0.794B | 121.41 |
| OraSure Technologies (OSUR) | United States | $0.772B | 43.48 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.756B | 24.24 |
| MacroGenics (MGNX) | United States | $0.740B | 0.00 |
| Cerus (CERS) | United States | $0.716B | 0.00 |
| PetIQ (PETQ) | United States | $0.705B | 20.03 |
| Lantheus Holdings (LNTH) | United States | $0.625B | 19.34 |
| Omeros (OMER) | United States | $0.619B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $0.540B | 26.52 |
| Owens & Minor (OMI) | United States | $0.535B | 6.05 |
| Insys Therapeutics (INSY) | United States | $0.527B | 0.00 |
| NanoString Technologies (NSTG) | United States | $0.521B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.444B | 0.00 |
| Evolus (EOLS) | United States | $0.403B | 0.00 |
| Quanterix (QTRX) | United States | $0.376B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.332B | 21.45 |
| Cytosorbents (CTSO) | United States | $0.313B | 0.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.264B | 0.00 |
| Surface Oncology (SURF) | United States | $0.225B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.214B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.204B | 275.00 |
| Chimerix (CMRX) | United States | $0.172B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.146B | 0.00 |
| Fonar (FONR) | United States | $0.141B | 7.06 |
| Imprimis Pharmaceuticals (IMMY) | United States | $0.123B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.106B | 0.00 |
| United-Guardian (UG) | United States | $0.080B | 16.85 |
| Female Health (VERU) | United States | $0.075B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | Israel | $0.070B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.066B | 21.07 |
| CAS Medical Systems (CASM) | United States | $0.053B | 0.00 |
| Neurotrope (NTRP) | United States | $0.048B | 0.00 |
| ImmuCell (ICCC) | United States | $0.043B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.029B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.018B | 0.00 |
| Senestech (SNES) | United States | $0.017B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
